Menu
Search
|

Menu

Close
X

Achieve Life Sciences Inc ACHV.OQ (NASDAQ Stock Exchange Capital Market)

3.59 USD
+0.21 (+6.21%)
As of 12:31 PM EDT
chart
Previous Close 3.38
Open 3.46
Volume 112,685
3m Avg Volume 6,913
Today’s High 3.94
Today’s Low 3.41
52 Week High 62.48
52 Week Low 3.30
Shares Outstanding (mil) 1.29
Market Capitalization (mil) 4.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
5
FY15
18
EPS (USD)
FY18
-2.431
FY17
-25.061
FY16
-73.919
FY15
-73.972
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.54
Price to Sales (TTM)
vs sector
--
8.28
Price to Book (MRQ)
vs sector
0.70
4.21
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.68
LT Debt to Equity (MRQ)
vs sector
0.00
13.20
Return on Investment (TTM)
vs sector
-93.69
13.09
Return on Equity (TTM)
vs sector
-93.82
15.10

EXECUTIVE LEADERSHIP

Richard Stewart
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Anthony Clarke
President, Chief Scientific Officer, Director, Since 2017
Salary: --
Bonus: --
John Bencich
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Since 2017
Salary: $307,500.00
Bonus: --
Cindy Jacobs
Executive Vice President, Chief Medical Officer, Since 2008
Salary: $413,225.00
Bonus: --
Donald Joseph
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

520 Pike St Ste 2250
SEATTLE   WA   98101-4013

Phone: +1425.6861500

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.

SPONSORED STORIES